Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Dimopoulos MA, Migkou M, Bhutani M, Ailawadhi S, Kalff A, Walcott FL, Pore N, Brown M, Wang F, Cheng LI, Kagiampakis I, Williams M, Kinneer K, Wu Y, Jiang Y, Kubiak RJ, Zonder JA, Larsen J, Sirdesai S, Yee AJ, Kumar S.
Dimopoulos MA, et al. Among authors: walcott fl.
Leuk Lymphoma. 2024 Dec;65(12):1789-1800. doi: 10.1080/10428194.2024.2373331. Epub 2024 Oct 15.
Leuk Lymphoma. 2024.
PMID: 39404476
Free article.
Clinical Trial.